GLORIA TM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced

- For non-US, UK & Canadian Media

Dubai, UAE, 20th April, 2012 – Boehringer Ingelheim announced today the launch of the GLORIA TM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.

With up to 56,000 patients planned for enrolment across 2,200 sites in 50 countries, GLORIA TM-AF will study treatment regimes available for stroke prevention in non-valvular AF and respective patient outcomes. The Registry Program will collect important data on the safety and comparative effectiveness of antithrombotic treatments, including vitamin K antagonist (VKA) warfarin, acetylsalicylic acid (ASA) and novel oral anticoagulants, such as dabigatran etexilate (Pradaxa®).